CCND1 and neoplasm: Recent advances have identified various biomarkers, such as Ki-67, Cyclin D1, Bmi-1, and EMT-related proteins, that enhance diagnostic accuracy and prognostic assessment, while emerging research into tumor mutational burden and metabolic pathways offers promising therapeutic targets.